About AxCell Labs.
AxCell Labs is a Canadian medical device company building the future of soft tissue reconstruction through regenerative biomaterials. Founded in 2021 during the co-founders’ academic research, the company develops implants designed to move beyond replacement and toward true tissue regeneration.
Our team
Jérémie Chaussé
CEP, MASc
Jérémie Chaussé is the co-founder and CEO of AxCell Labs, a Canadian medtech company developing a new generation of soft tissue implants using bacterial cellulose. Trained in biotechnological engineering, he has led AxCell Labs from concept to advanced preclinical validation, securing over $1.4M in oversubscribed financing alongside non-dilutive funding, and building strategic collaborations with surgeons, research institutions, and industry partners. His work is centered on unlocking the clinical potential of bacterial cellulose as a fully biocompatible, implantable material aiming to redefine standards in both reconstructive and aesthetic medicine.
Vincent-Daniel Girard
CEP, MASc
Vincent-Daniel Girard is Vice President, Co-Founder and Chief Scientific Officer at AxCell Labs. Passionate about agri-food biotechnology, Vincent-Daniel has nearly 5 years’ practical experience in bacterial, yeast and fungal fermentation. Having completed his master’s degree on the in vitro and in vivo biocompatibility of bacterial cellulose, Vincent-Daniel adds mammalian cell culture to his skills, as well as the design and execution of experimental protocols on live models. Co-founder of AxCell Labs, Vincent-Daniel uses his knowledge to catalyze the ongoing development of bacterial cellulose, bringing a high-value-added product to market.
Jordan Mailloux
BSC, MSC
Jordan Mailloux is an R&D and QA Scientist at AxCell Labs. His academic background started in biotechnology, where he developed a strong interest in bioprocesses and microbiology, in which he pursued his graduate studies. Jordan holds an M.Sc. in Biology from the Université de Sherbrooke, where he developed a high-throughput CRISPR-based bacterial synthetic genetic array. His expertise in microbiology and method development, combined with his experience in high-throughput data analysis and quality control, plays a crucial role in advancing Axcell Labs’ mission. As an avid nature enthusiast, Jordan can often be found hiking in the mountains, camping, or enjoying the summer weather on a local microbrewery patio. He is also a passionate Ultimate Frisbee player.
Marine Ferron
Ph.D
Marine Ferron is a research coordinator with extensive expertise in therapeutic strategies for cardiac and inflammatory diseases. From her university studies in France to her post-doctorate in Montreal, Marine has developed and refined her skills in pre-clinical research, becoming a valuable asset for the advancement of AxCell Labs’ projects. In her spare time, Marine enjoys spending time with her family and horseback riding, combining serenity with a passion for nature.
Advisors
Dominique Dorion
MD, MSc, FRCSC, FACS
Born in Quebec City in another millennium, Dominique Dorion graduated in medicine from Laval University in 1985. This was followed by 6 years of complementary training in cervico-facial oncology and microvascular reconstruction at the University of Toronto. Based in Sherbrooke since 1993, he has chaired numerous committees in Canada and around the world. He was recognized by his peers with a “Oeuvre d’une vie” award in 2021 by the Canadian ENT Association. Dean of Sherbrooke’s Faculty of Medicine and Health Sciences since 2017, he promotes commitment, passion and social responsibility.
Christian Iorio-Morin
MD, PhD, FRCSC
Christian Iorio-Morin is a clinical neurosurgeon-researcher. After graduating from the Université de Sherbrooke’s neurosurgery program in 2019, he completed a fellowship in functional neurosurgery at the University of Toronto, before moving to CIUSSS de l’Estrie-CHUS to set up a deep brain stimulation program. His career combines surgery, research and entrepreneurship. He is involved in several start-ups to facilitate technology transfer and accelerate the time-to-market of promising technologies.
Claude Leduc
Claude, co-founder, president, and CEO of RNA Technologies & Therapeutics, is a visionary leader with 38 years of experience in the biopharma industry. He has held key roles in private ventures and Fortune 500 companies, including Syntex Labs, Serono Labs, Biomatrix, and Genzyme Biosurgery, focusing on sales, marketing, and international business development. A renowned serial entrepreneur and investor, Claude has guided numerous successful ventures from R&D to market launch in fields such as regenerative medicine and biopolymers. He has raised over $70 million in equity and debenture notes, driving RNA Technologies & Therapeutics toward new heights of success.